CoChat

The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience

Open access
Hiatt, William R., Kaul, Sanjay, Smith, Robert J. · 2013 · New England Journal of Medicine

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Related articles

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmp1309610

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 6 references

Cited by

See all 204

Metadata

Authors
Hiatt, W. R., Kaul, S., & Smith, R. J.
Affiliations
  • University of Colorado Anschutz (US)
  • Cedars-Sinai Medical Center (US)
  • Brown University (US)
Venue
New England Journal of Medicine
Published
2013-10-03
Volume
369
Issue
14
Pages
1285-1287
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2329117883
Cited by
204
References
6
Citations by year
2026: 3 · 2025: 3 · 2024: 10 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 15 · 2019: 23 · 2018: 24 · 2017: 14 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 6
FWCI
23.32
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
cardiovascular safety, diabetes drugs, rosiglitazone, thiazolidinediones, cardiovascular adverse events, drug safety
MeSH terms
Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Europe, Humans, Hypoglycemic Agents, Myocardial Infarction, United States, United States Food and Drug Administration, Drug Approval, Thiazolidinediones, Safety-Based Drug Withdrawals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience. https://app.cochat.ai/papers/10.1056/nejmp1309610
The paper
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013). The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience. New England Journal of Medicine. https://doi.org/10.1056/nejmp1309610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.